ArticleFrontiers in aging neuroscience2017
Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.
Article in Frontiers in aging neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.Annals of neurology · 2025Article
- Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.Brain communications · 2024Article
- Can Genetic Markers Predict the Sporadic Form of Alzheimer's Disease? An Updated Review on Genetic Peripheral Markers.International journal of molecular sciences · 2023Review
- Review
- Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.Alzheimer's research & therapy · 2022Article
- Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint.Frontiers in neuroscience · 2022Review
- Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.Journal of internal medicine · 2021Review
- Microglia Biomarkers in Alzheimer's Disease.Molecular neurobiology · 2021Review
- Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.Translational psychiatry · 2021Article
- Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.Acta neuropathologica communications · 2021Article
- The Diagnostic Potential of Amyloidogenic Proteins.International journal of molecular sciences · 2021Review
- Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.Brain sciences · 2021Review
- Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry.Journal of Alzheimer's disease : JAD · 2021Article
- Amyloid-βAlzheimer's research & therapy · 2020Article
- Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2020Review
- Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.Alzheimer's research & therapy · 2020Review
- Early-onset Alzheimer Disease and Its Variants.Continuum (Minneapolis, Minn.) · 2019Review
- Current state of Alzheimer's fluid biomarkers.Acta neuropathologica · 2018Review
- Microbiome-Derived Lipopolysaccharide (LPS) Selectively Inhibits Neurofilament Light Chain (NF-L) Gene Expression in Human Neuronal-Glial (HNG) Cells in Primary Culture.Frontiers in neuroscience · 2018Article
- The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DISCUSSION: Cerebrospinal fluid Aβ43, but not Aβ42 levels, varied significantly with age in patients with AD. If CSF levels of Aβ peptides reflect amyloid deposition in brain, the possibility arises that there is a difference between Aβ43 and Aβ42 deposition in younger compared to older brain. However, the level of Aβ43 in CSF shows no improvement over Aβ42 regarding diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.